Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Policy Veterans’ Group Advocates Drug Reimbursement at Actual Purchase Prices
An independent study group of policy veterans, dubbed Kusuri Mirai Juku, on October 27 proposed the stepwise introduction of a new system to reimburse drugs used by medical institutions at their purchase prices. If such system is introduced, medical institutions…
To read the full story
Related Article
- Policy Veterans’ Group Calls for Value-Based Pricing for Regenerative Medicine
November 14, 2025
- Policy Veterans’ Group Calls for Inflation-Linked Drug Pricing in FY2026 Reform
October 1, 2025
- Policy Veterans’ Group Opposes Expansion of CEA Price Adjustments
June 13, 2025
- Policy Veterans’ Group Urges Japan to More than Double Minimum Drug Prices
February 21, 2025
- Policy Veterans’ Group Proposes Special Drug Price Rule for Antibiotics
October 3, 2024
- Policy Veterans’ Group Renews Call for Company-Proposed Pricing, Floats Support System for Biosimilars
November 15, 2023
- Discuss Multi-Faceted Evaluation of Drugs Ahead of Lecanemab Approval: Policy Veterans’ Group
May 10, 2023
- Policy Veterans’ Group Floats Proposal to Prevent Unprofitability to Stabilize Drug Supply
February 21, 2023
- Deloitte Proposes Pricing Schemes to Encourage Consolidation of Generic Makers
October 31, 2022
- Ex-Bureaucrats, Academics Trade Barbs over Macroeconomic Indexing; Will MOF Allow Rise in Drug Cost?
October 28, 2022
- Veterans’ Group Proposes Timely Drug Re-Pricing with Online Data, Reimbursement at Actual Purchase Prices
July 27, 2022
REGULATORY
- Takeda’s Miyabashira Urges National Strategy Act to Revive Japan as Innovation Powerhouse
January 22, 2026
- LDP Pledges to Position Pharma as Core Industry in Campaign Platform
January 22, 2026
- Many Pharma-Savvy Lawmakers on LDP’s Candidate Roster for Lower House Poll
January 22, 2026
- Japan Health Minister Says Early Call on FY2027 Off-Year Revision Improves Predictability
January 22, 2026
- Japan Grants Sakigake Tag to Nanoscope’s MOGENRY
January 22, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…